RxDoctor Payments Data

Sukhjot Kaur, NP

Family · Bakersfield, CANPI 1194276923

Payments from drug & device makers

$904in general payments, 2019–2025

Across 46 payments — averaging $19.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$181
  • Novo Nordisk$167
  • AbbVie$131
  • Merck$82
  • Amgen$61
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$47
  • plus $236 from 9 others

What the payments were for

  • Food & beverage$81790%
  • Education$8710%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$904 in reported general payments places this provider in the 70th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$53,509
Medicare patients
129
Services billed
4,996

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Teriparatide70$205,249
FarxigaDapagliflozin Propanediol183$159,042
ForteoTeriparatide35$155,297
RybelsusSemaglutide43$64,669
ProliaDenosumab22$38,949
VelphoroSucroferric Oxyhydroxide17$32,870
LokelmaSodium Zirconium Cyclosilicate37$29,015
EliquisApixaban45$28,186
OzempicSemaglutide31$28,109
JardianceEmpagliflozin21$21,883
VeltassaPatiromer Calcium Sorbitex17$17,146
LinzessLinaclotide15$15,296
TradjentaLinagliptin12$13,675
Pantoprazole Sodium97$9,234
Famotidine179$6,099

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$181$188,057220 claims
Novo NordiskRybelsus, Ozempic$167$92,77874 claims
AmgenProlia$61$38,94922 claims
AbbVieLinzess$131$15,29615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,634 family providers in California.

Other family in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →